Results 131 to 140 of about 12,584 (301)
GENETIC SPECTRUM OF PRIMARY DYSLIPIDEMIAS IN CHILDREN - SINGLE CENTER EXPERIENCE
Primary dyslipidemias are heterogenous metabolic disorders caused by pathogenic genetic variants. Over 100 genes have been identified that impact lipid metabolism, with familial hypercholesterolemia being the most common form, occurring in the general ...
Sarajlija, Adrijan +8 more
core
, 2009 Several large-scale clinical trials have shown that lipid- lowering interventions are associated with reduced coronary events and mortality, However, whether dyslipidemias have a detrimental effect on the evolution of myocardial infarction (MI) is still ...
王宗道;吳造中;陳文鍾;李啟明;陳明豐;廖朝崧;宋鴻樟;李源德 +1 more
core
Clinical Pharmacology &Therapeutics, EarlyView.Statin‐associated muscle symptoms (SAMS) are frequent adverse effects of statin therapy and have been hypothesized to result from impaired coenzyme Q10 (CoQ10) biosynthesis. Although genetic determinants of CoQ10 levels have been reported, genome‐wide association studies (GWASs) conducted specifically in statin users are lacking. Moreover, direct CoQ10
Da Hoon Lee +6 more
wiley +1 more source
New Strategies in the Treatment of Dyslipidemias
My thesis, New Strategies in the Treatment of Dyslipidemias, examines both established and emerging approaches to managing lipid disorders that contribute significantly to atherosclerotic cardiovascular disease.
Fiebai, Olaowei
core
Clinical Pharmacology &Therapeutics, EarlyView.CYP2C19 and CYP3A4 contribute to clopidogrel bioactivation. CYP2C19 no‐function alleles diminish clopidogrel's antiplatelet effects and clinical effectiveness. Coadministration of either a CYP2C19 or a CYP3A4 inhibitor may also reduce clopidogrel's antiplatelet effects and lead to phenoconversion in patients without a CYP2C19 no‐function allele (normal/
Danwei Shao +8 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Obeticholic acid (OCA), a synthetic analog of chenodeoxycholic acid, was approved in 2016 for the treatment of primary biliary cholangitis. Early clinical trials revealed elevated liver biomarkers in healthy subjects receiving supratherapeutic OCA doses (100–250 mg).
Abigail K. Mayo +4 more
wiley +1 more source
Salud Pública de México, 2010 OBJECTIVE: To describe the prevalence of hypertension among Mexican adults, and to compare to that observed among Mexican-Americans living in the US.
Simón Barquera +6 more
doaj
Dyslipidemias: management and role of the pharmacist in the observance of treatments
, 2021 Les maladies cardio-vasculaires restent aujourd’hui en France et en Europe la deuxième cause de mortalité après les cancers tout type confondu. Les dyslipidémies représentent une des principales causes de complication cardio-vasculaire.
LASSALLE, Judith
core
Novel Organelle‐Based Intracellular Immunity With Mechanistic and Therapeutic Implications
Barrier Immunity, EarlyView.A conceptual framework illustrating how PAMPs/DAMPs initiate barrier, innate, adaptive, and intracellular immune responses, with organelle‐based intracellular immunity serving as a central integrator linking metabolism, inflammatory signaling, and therapeutic interventions to restore immune homeostasis.
Keman Xu +9 more
wiley +1 more source
Secretopathies emerge as a new class of neurocristopathies
Developmental Dynamics, EarlyView.Abstract Neural crest cells are a transient embryonic population of cells that give rise to a wide range of structures, including craniofacial cartilage and bone, peripheral neurons and glia, as well as components of the cardiac outflow tract, among others.
Amanda Teixeira +3 more
wiley +1 more source